New Rules of Global Pharma: When Everything Changes at Once

Lasting Supply: Rebuilding Europe’s Antibiotic Manufacturing Resilience

Beyond Regulatory Reform: How Biosimilar Development Is Reshaping Market Access and Manufacturing Strategy

Value Added Medicines and Differentiated Generics

Canada's Biomanufacturing Advantage - Turning Innovation into Global Partnerships

From Molecule to Market: Accelerating Oral Delivery of Peptides through Integrated Global Pharma Solutions and Advanced Enteric Technologies

Global API Manufacturing: Market Shifts, Competitive Dynamics, and the Road Ahead

From Compliance to Competitive Advantage: Unlocking the Business Value of Pharmacovigilance

From Innovation to Access: Building Scalable Care Pathways for Next-Generation Therapies in Emerging Markets

Keynote: Shifting Geopolitical Dynamics in Pharmaceutical Innovation and Supply

Market Access Under Pressure: Pricing, Policy, and Global Pharmaceutical Economics

Powering Pandemic Preparedness - Voluntary Licensing & Generic Collaborations

Geopolitical Tensions and Supply Chain Fragmentation: How Site-Neutral Manufacturing Addresses the Three-Block Reality

MDR 2017/745: Where Compliance Becomes Trust in Substance-Based Medical Devices

Enabling Efficient and Scalable mRNA Manufacturing: A new Technology to Control dsRNA Formation in IVT reaction

Enabling Unbiased Container Selection: Large-Volume IV & SC Drug Delivery Solutions

China's Innovation Ascendancy: Implications for Global Licensing Dynamics

The New Pharmaceutical World Order: Winners and Losers by 2030

Local Scale, Global Ambition: Rewiring Pharma's Supply Chain

The Personalisation Challenge: Designing Medicines That Perform Beyond the Primary Market

Delivering the Next Generation of Biotherapies: Execution Realities and Smart Packaging Trade-offs

Packaging & Device Strategies for Biosimilars and GLP-1s: Using Co-Development to Navigate Financial Hurdles

Issue of Container Closure Integrity at Cell & Gene Therapy Products

Strategic CDMO Partnerships in Combination Drug–Device Development: Accelerating Time to Market While Mitigating Risks

Navigating Injection Device Selection: Translating Pharma Drivers into Development Decisions

Future-Ready ADCs – Advanced Vial Solutions for Superior Stability and Performance

Regional Insight: Southeast Asia and the Future of Pharma Packaging

How GLP-1 Therapies Are Reshaping Pharmaceutical Manufacturing, Drug Delivery, and Supply Chain Economics

Designing Drug Delivery for Rare Disease

From Infusion to Self-Injection: The New Era of Subcutaneous Drug Delivery

Patient Experience Defines the Future: The Evolution of Nasal Products in Upper Respiratory Conditions

When Patients Trust, Processes Must Prove: Automating Line Clearance for Safer Medicines

Rethinking Oral Drug Delivery: From Manual Dose Measurament to Device-Guided Dosing

Direct CCI Testing of Fully Assembled Autoinjectors Using Headspace Analysis

Panel: Large Volume Drug Delivery Trade Off: The Patient Choice Dilemma

Panel: Digital Integration Across Packaging, Labelling and Product Information

Optimising Injectability of High-Viscosity Biologics In Next-Generation Syringe-Based Autoinjectors

Platform Autoinjector Technologies for Enabling Next-Generation Combination Products

Pressures and Strategic Imperatives of Resiliency: Rethinking Pharma Supply Chains

Rapid Agile Manufacturing Partnerships for Union Protection

API Security in a Fragmented World: Navigating the New Global Supply Chain Reality

Building Global API Supply Chains on Solid Foundations: The Role of the Ph. Eur. and the EDQM’s Primary Reference Standards

Targeting Skin pH: A Novel Topical Approach for Atopic Dermatitis

Medical Nutrition Beyond Hospitals - How FSMP and Disease-Specific ONS Can Support Recovery and Long-Term Care

Controlling Excipient-Derived Impurities to Minimize Particulate Formation in Injectable Formulations

Supply Chain Intelligence for Upstream Risk: Seeing the Hidden Network Before It Breaks

Panel: The Next Phase of Pharma Supply Chains

From Commodity to Critical: Reframing APIs for Complex Formulations and Resilient Supply

Panel: Are innovation and Excipients Mutually Exclusive?

Flowing Beyond the Lab: How Green Chemistry Drives Water Stewardship

From Injection to Oral: Expanding the Possibilities for Oral Delivery of Macromolecules

Nitrosamine Risk Mitigation: From Regulatory Expectations to Practical Implementation

Building the Future of Bioconjugate Supply: Integrating Payload-Linkers, Manufacturing and Commercial Scale-Up

Overcoming QS-21 Supply Constraints: A Scalable GMP Approach for Global Vaccine Preparedness

PFAS and Pharmaceutical Resilience: Preparing for Wastewater Regulations with Innovative PFAS Destruction Technologies

Panel: From Commodity to Critical: Rethinking the Role of Pharmaceutical Ingredients

Bioactivation at Scale: From Discovery to Manufacturing Excellence in the Next Generation of Natural Products

Nutraceuticals: Scaling Without Breaking Supply

Beyond Polymorphs: Turning Solid-State Knowledge into Formulation Development Advantage

Beyond the Pipeline: Why Breakthrough Science Fails at the Point of Execution

Cell & Gene Therapy: Bridging Innovation and Commercial Reality

mRNA Beyond COVID: Scaling Platform Technologies for Oncology

Accelerating the Medicines of Tomorrow to IND: Building Next-Generation Biologics with Future Clinical Success in Mind

Every mL Counts: Maximize Yield and Minimize Hold‑Up Volume With Automated Filling

EnzeneX® - An Innovation that Became an Industry Imperative

Living Medicines: Can Manufacturing Infrastructure Keep Pace with Progress?

Panel: ADC Manufacturing Complexity: Technical Execution Challenges

Keynote: Europe's Biotech Act II: Setting the Manufacturing Foundation

Beyond the Blueprint: Executing Europe's Bio-Manufacturing Vision

Understanding the Patenting Landscapes of Strategic Biotech Technology Areas

Building a BsAb CMC Playbook: Decision Frameworks, Risks, and Readiness

Resilience Is the New Capacity: Building Manufacturing Advantage Through Strategic CDMO Partnerships

Strategic Advice: FDA, CDMOs/CMOs and ATMPs

Closing the Digital Execution Gap - Cross-Company Data Exchange via the Pharma Open Data Space

Panel: From Reactive to Predictive: Manufacturing Intelligence in Biologics Production

Panel: When Innovation Outruns Infrastructure

Smart Technology, Skilled Teams: Building Agile Aseptic Operations

Breaking the Batch Paradigm: Continuous Biomanufacturing at Commercial Scale

Scaling the Future of Medicine With AI

Building Manufacturing Capabilities for Next-Generation Medicines

Panel: CDMO Consolidation: Strategic Partnerships or Dangerous Dependencies?

FDA's America First Agenda: Reshaping Global Pharma Manufacturing

Accelerating Speed-to-Market for OTC Products: Technical, Regulatory and Cost Considerations

The Future of Commercial Spray Drying: Supporting the Medicines of Tomorrow

Extractables & Leachables in Transition: Toward a Unified Risk-Based Approach

The Human Advantage: The New Rules of Successful Pharma Outsourcing. Why Human Partnership is Becoming More Important in an Age of AI, Digitalisation and Supply Chain Complexity

Tech Transfer Timelines: The Hidden Constraint on Manufacturing Flexibility

GLP-1 Manufacturing Evolution: Scaling Innovation for Injectable and Oral Therapies

Building the Future of Manufacturing: The Leadership Behind Digital Transformation

Panel: AI Ask Us Anything: The Scale-Up Edition

Putting AI to work in drug Development: Practical applications that deliver measurable value

Slowing Down to Speed Up: The Planning Principles Behind Successful Technology Transfers

From Innovation to Commercial Excellence: Tailored Manufacturing of Peptides and Beta-Lactam APIs in Europe

Nitrosamines Beyond Compliance: Practical Strategies and Real-World Case Studies

Building the Regulatory Case: How to Use In Silico Modeling as an Accelerator in CMC Submissions Without Creating New Risk

Panel: Scaling Digital Manufacturing: From Pilot Success to Production Reality

Navigating the CDMO Landscape: Market Trends, Emerging Opportunities, and the China Impact

Panel: CDMO Strategic Inflection Point: From Capacity Provider to Innovation Architect

From Global to Local: Building Resilient Pharma Supply Chains Through Local-for-Local Manufacturing

Accelerate Timeline to Start PhI: Phase Appropriate Development and Integrated Drug Product Supply

CDMO Facilities: Tracking Trends in the Sector’s Expansion

Bright Light, Big Scale: Unlocking Industrial Photochemistry